Breaking News Instant updates and real-time market news.

MOR

MorphoSys

$27.63

-0.105 (-0.38%)

, JNJ

Johnson & Johnson

$145.38

-0.52 (-0.36%)

05:06
12/10/18
12/10
05:06
12/10/18
05:06

MorphoSys upgraded to Buy from Hold at Deutsche Bank

Deutsche Bank analyst Gunnar Romer upgraded MorphoSys (MOR) to Buy and raised his price target for the shares to EUR 130 from EUR 120. The company's 115 antibody drug candidates offer "best-in-class risk diversification and value-creation potential," Romer tells investors in a research note. Further, he believes Tremfya, which is partnered with Johnson & Johnson (J&J), is on its way to becoming a multi-billion blockbuster.

MOR

MorphoSys

$27.63

-0.105 (-0.38%)

JNJ

Johnson & Johnson

$145.38

-0.52 (-0.36%)

  • 12

    Dec

  • 12

    Dec

MOR MorphoSys
$27.63

-0.105 (-0.38%)

11/05/18
PIPR
11/05/18
INITIATION
Target $38
PIPR
Overweight
MorphoSys initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Danielle Brill started MorphoSys with an Overweight rating and $38 price target. Despite last week's rally, the analyst thinks the company's lead asset MOR208 remains underappreciated. The data look "significantly better than other high-profile drugs in development," Brill tells investors in a research note. She expects good adoption of the drug and thinks MorphoSys shares are undervalued
11/28/18
PIPR
11/28/18
NO CHANGE
Target $38
PIPR
Overweight
MorphoSys's MOR208 remains key focus for company, says Piper Jaffray
Piper Jaffray analyst Danielle Brill kept her Overweight rating and $38 price target on MorphoSys following her meeting with its CEO Simon Maroney at Piper Jaffray Healthcare Conference. The analyst notes that the company remains focused on the development of MOR208 and believes that the drug could become "cornerstone" of Diffuse Large B-Cell Lymphoma, or DBLCL, therapy, remaining "very bullish" on the name. Brill adds that her survey of doctors treating lymphoma at the conference revealed that 46% would use MOR208 for their DBLCL patients.
12/02/18
PIPR
12/02/18
NO CHANGE
Target $38
PIPR
Overweight
MorphoSys' MOR208 ASH data 'remarkable,' says Piper Jaffray
Piper Jaffray analyst Danielle Brill notes that MorphoSys presented MOR208 data at ASH, and says she is particularly encouraged that MOR208 efficacy is consistent across of cell-of-origin and in rituximab refractory patients. "It's difficult to poke holes in the data which were deemed remarkable by the lead investigator," she contends. Brill thinks MOR208 has made it onto the radar screens of physicians and has huge potential in DLBCL. Additionally, the analyst thinks the next likely catalyst is an "attractive partnership" for MOR208 development and commercialization outside of the U.S. She reiterated an Overweight rating and $38 price target on the shares.
12/06/18
PIPR
12/06/18
NO CHANGE
Target $38
PIPR
Overweight
MorphoSys share setup remains positive, says Piper Jaffray
Updates at MorphoSys AG's investor day were incremental, though future development plans for MOR208 in front-line diffuse large B-cell lymphoma were outlined, Piper Jaffray analyst Danielle Brill tells investors in a research note. While the analyst hoped pivotal development in the front-line setting would begin sooner than mid-2020, she appreciates "de-risking" the program by running a small study first. She continues to think the setup for MorphoSys is positive and keeps an Overweight rating on the shares with a $38 price target.
JNJ Johnson & Johnson
$145.38

-0.52 (-0.36%)

11/12/18
PIPR
11/12/18
NO CHANGE
Target $25
PIPR
Overweight
Arrowhead's new data validate TRiM pipeline, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff believes new data presented by Arrowhead (ARWR) at the AASLD meeting on ARO-AAT and ARO-HBV validate the company's proprietary TRiM platform. He expects a potentially registrational Phase 2/3 trial for ARO-AAT to start in the first quarter of 2019 and noted that partner Janssen (JNJ) intends to begin Phase 2 studies of ARO-HBV in the first half of next year. Tenthoff keeps an Overweight rating and $25 price target on Arrowhead shares.
11/13/18
LEER
11/13/18
INITIATION
Target $18
LEER
Outperform
AC Immune initiated with an Outperform at Leerink
Leerink analyst Marc Goodman started AC Immune with an Outperform and $18 price target as he initiates Neuroscience space with a Positive View. The analyst believes the Neuroscience sector is experiencing a "renaissance" as multiple new agents and mechanisms are coming up the pipeline across major therapeutic areas, the number of clinical studies is growing nicely, and the FDA is friendly to innovation in this space, companies are getting smarter about speed-to-market strategies and selecting niche sub-populations to focus on for initial product approvals, payer pushback on usage is much lower than in other categories, and physicians are enthusiastic about new agents. Regarding AC Immune, Goodman notes that it has a diversified pipeline of drug candidates and diagnostics for Alzheimer's disease led by a late stage antibody with crenezumab, and has strong partners with Roche (RHHBY) for crenezumab, Johnson & Johnson (JNJ) for Anti-Tau vaccine, Biogen (BIIB) for alphasynuclein-PET tracer diagnostic, and Piramal for TauPET tracer diagnostic.
11/19/18
WELS
11/19/18
NO CHANGE
WELS
Pfizer price hikes may bring industry scrutiny, says Wells Fargo
Pfizer's (PFE) plans to raise prices on a host of medicines may put the drug industry "further in the crosshairs of an administration and Congress that is set on lowering drug prices," Wells Fargo analyst David Maris tells investors in a research note. The analyst points out that Pfizer earlier this year was criticized by the Trump administration for drug price increases, and as a result, it rolled the price increases back. However, Pfizer's new price increases "are not egregious" and its advance warning may be an attempt to see if minor price increases will also bring the administration's rebuke, says Maris. Nonetheless, given how public the administration's previous rebuke was, the analyst thinks Pfizer's confirmation Friday could "enflame the debate around drug pricing, especially since it comes less than two weeks following an election that resulted in Democrat control of the House with many having run on a drug-price-controls/Medicare-for-All platforms." Other large drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
12/03/18
PIPR
12/03/18
NO CHANGE
PIPR
Argenx price target raised to $161 from $154 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating on Argenx and raised his price target on shares to $161 from $154. Tenthoff noted that after the company announced a 92% response rate for 11/12 AML patients in the Phase I cusatuzumab plus azacitidine study, it signed a global licensing deal with Johnson & Johnson (JNJ)/Janssen's European subsidiary Cilag for $300M in cash and a $200M equity investment, bringing pro forma cash to $1.16B. The analyst also noted that Argenx was eligible for $1.3B in milestones and that it retained 50/50 U.S. profit share and double-digit OUS royalties. Tenthoff concluded that "the updated analysis removes any concern investors had over bleeding events."

TODAY'S FREE FLY STORIES

EH

Ehang

$0.00

(0.00%)

10:39
12/12/19
12/12
10:39
12/12/19
10:39
Syndicate
Ehang indicated to open at $12.25, IPO priced at $12.50 »

Ehang (EH) 3.2M share IPO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

WDDMF

WeedMD

$0.00

(0.00%)

, ACB

Aurora Cannabis

$2.46

(0.00%)

10:37
12/12/19
12/12
10:37
12/12/19
10:37
On The Fly
Rising High: An exclusive talk with medical-grade cannabis producer WeedMD »

In this edition of…

WDDMF

WeedMD

$0.00

(0.00%)

ACB

Aurora Cannabis

$2.46

(0.00%)

TLRY

Tilray

$18.68

0.49 (2.69%)

ZYNE

Zynerba

$5.68

0.06 (1.07%)

CGC

Canopy Growth

$20.35

0.05 (0.25%)

CTST

CannTrust

$0.81

-0.0102 (-1.24%)

CRON

Cronos Group

$6.89

0.07 (1.03%)

IGC

India Globalization Capital

$0.67

0.0047 (0.71%)

CVSI

CV Sciences

$0.00

(0.00%)

CANN

General Cannabis

$0.00

(0.00%)

TCNNF

Trulieve Cannabis

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

  • 17

    Dec

PTVCA

Protective Insurance

$15.36

(0.00%)

10:36
12/12/19
12/12
10:36
12/12/19
10:36
Hot Stocks
Breaking Hot Stocks news story on Protective Insurance »

Protective Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADSK

Autodesk

$178.55

-1.315 (-0.73%)

10:35
12/12/19
12/12
10:35
12/12/19
10:35
Options
Autodesk put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BILL

Bill.com

$0.00

(0.00%)

10:35
12/12/19
12/12
10:35
12/12/19
10:35
Syndicate
Breaking Syndicate news story on Bill.com »

Bill.com indicated to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

USO

United States Oil Fund

$12.45

0.16 (1.30%)

10:34
12/12/19
12/12
10:34
12/12/19
10:34
General news
EIA natural gas storage change for week ending December 6 »

Gas inventories 73 Bcf…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTVCA

Protective Insurance

$15.36

(0.00%)

10:31
12/12/19
12/12
10:31
12/12/19
10:31
Hot Stocks
Breaking Hot Stocks news story on Protective Insurance »

Protective Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KRUS

Kura Sushi

$25.45

0.32 (1.27%)

10:31
12/12/19
12/12
10:31
12/12/19
10:31
Downgrade
Kura Sushi rating change  »

Kura Sushi downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:30
12/12/19
12/12
10:30
12/12/19
10:30
General news
Fed funds futures have slipped as risk appetite climbs »

Fed funds futures have…

BILL

Bill.com

$0.00

(0.00%)

10:27
12/12/19
12/12
10:27
12/12/19
10:27
Syndicate
Breaking Syndicate news story on Bill.com »

Bill.com indicated to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

ZYME

Zymeworks

$42.45

0.3 (0.71%)

, AZN

AstraZeneca

$48.38

0.19 (0.39%)

10:26
12/12/19
12/12
10:26
12/12/19
10:26
Recommendations
Zymeworks, AstraZeneca analyst commentary  »

Zymeworks may have…

ZYME

Zymeworks

$42.45

0.3 (0.71%)

AZN

AstraZeneca

$48.38

0.19 (0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

WCN

Waste Connections

$90.12

-0.03 (-0.03%)

10:25
12/12/19
12/12
10:25
12/12/19
10:25
Conference/Events
Waste Connections participates in a conference call with UBS »

Environmental Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

10:25
12/12/19
12/12
10:25
12/12/19
10:25
Conference/Events
JPMorgan telecom services analyst to hold an analyst/industry conference call »

Telecom Services/Cable…

SGH

Smart Global

$31.00

0.53 (1.74%)

10:21
12/12/19
12/12
10:21
12/12/19
10:21
Options
Smart Global option volume jumps as rescheduled earnings date spikes December »

Smart Global option…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

ALG

Alamo Group

$116.31

-0.1 (-0.09%)

10:19
12/12/19
12/12
10:19
12/12/19
10:19
Conference/Events
Alamo Group management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
12/12/19
12/12
10:17
12/12/19
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
12/12/19
12/12
10:16
12/12/19
10:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MG

Mistras

$13.96

0.12 (0.87%)

10:15
12/12/19
12/12
10:15
12/12/19
10:15
Conference/Events
Mistras management to meet with Sidoti »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

PPL

PPL Corp.

$33.93

0.17 (0.50%)

10:15
12/12/19
12/12
10:15
12/12/19
10:15
Options
PPL Corp. put volume heavy and directionally bearish »

Bearish flow noted in PPL…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
12/12/19
12/12
10:15
12/12/19
10:15
General news
FX Action: USD-JPY »

FX Action: USD-JPY…

10:15
12/12/19
12/12
10:15
12/12/19
10:15
General news
Breaking General news story  »

Week of 12/6 EIA Natural…

10:15
12/12/19
12/12
10:15
12/12/19
10:15
General news
Breaking General news story  »

Week of 12/6 EIA Natural…

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$316.72

2.305 (0.73%)

10:14
12/12/19
12/12
10:14
12/12/19
10:14
Periodicals
U.S. offers to cancel upcoming round of China tariffs, WSJ reports »

U.S. trade negotiators…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$316.72

2.305 (0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DL

China Distance Education

$8.05

(0.00%)

10:10
12/12/19
12/12
10:10
12/12/19
10:10
Conference/Events
China Distance Education management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

  • 17

    Dec

BILL

Bill.com

$0.00

(0.00%)

10:10
12/12/19
12/12
10:10
12/12/19
10:10
Syndicate
Bill.com indicated to open at $30.00, IPO priced at $22.00 »

Bill.com (BILL) priced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.